{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:12:10Z","timestamp":1788426730290,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019559","name":"Carl von Ossietzky Universit\u00e4t Oldenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019559","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) is an incurable plasma cell malignancy with relapses and diminishing response durations. Preclinical studies suggest that time-restricted eating (TRE)-related metabolic changes may enhance chemosensitivity by exploiting cancer cell vulnerabilities to nutrient deprivation. Clinical data in solid tumours remain limited and heterogeneous, mainly supporting feasibility and possible toxicity reduction rather than definitive efficacy. While efficacy has been explored in breast cancer patients, there is a lack of data for haematological patients, including MM. FASTINA (Fasting in Staging of MM \u2013 Intervention for Nutritional Adherence) will therefore primarily assess feasibility and safety and will explore preliminary efficacy of incorporating TRE into standard MM therapy. FASTINA is a single-centre, open-label, parallel-group randomised controlled feasibility trial (DRKS00034370). 54 adults with MM will be randomised 1:1 to either 16:8 TRE\u2009+\u2009nutritional counselling or nutritional counselling alone for 12\u00a0weeks during systemic therapy. Primary endpoints are adherence to the diet (adherence\u2009\u2265\u200980%) and complete response with measurable residual disease (MRD) negativity at treatment end. Secondary endpoints include response rates, nutritional status, body composition changes, frequency of\u2009\u2265\u2009grade 3 adverse events (AEs), progression-free (PFS) and exploratory overall survival (OS), quality of life (QoL), and fatigue. FASTINA will evaluate whether TRE is feasible and safe in selected MM patients and whether there is a hypothesis-generating signal for improved treatment response, informing the design of a subsequent phase II trial.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration<\/jats:bold>\n                    Deutsches Register Klinischer Studien (DRKS), DRKS00034370. Registered 21 June 2024,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/drks.de\/search\/de\/trial\/DRKS00034370\" ext-link-type=\"uri\">https:\/\/drks.de\/search\/de\/trial\/DRKS00034370<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1186\/s40814-026-01914-7","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:56:13Z","timestamp":1788422173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FASTINA \u2013 protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy"],"prefix":"10.1186","volume":"12","author":[{"given":"Anna Franziska","family":"Hamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vorwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona Maria","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Smollich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schwitlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inke Regina","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Oelschl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Khandanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"3","key":"1914_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.critrevonc.2013.01.005","volume":"87","author":"VN Anisimov","year":"2013","unstructured":"Anisimov VN, Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol. 2013;87(3):201\u201323.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1914_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3892\/mmr.2015.3560","volume":"12","author":"A Bahhnassy","year":"2015","unstructured":"Bahhnassy A, Mohanad M, Shaarawy S, Ismail MF, El-Bastawisy A, Ashmawy AM, et al. Transforming growth factor-\u03b2, insulin-like growth factor I\/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer. Mol Med Rep. 2015;12(1):851\u201364.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1914_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4353-2","volume":"18","author":"SP Bauersfeld","year":"2018","unstructured":"Bauersfeld SP, Kessler CS, Wischnewsky M, Jaensch A, Steckhan N, Stange R, et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomised cross-over pilot study. BMC Cancer. 2018;18(1):476.","journal-title":"BMC Cancer"},{"issue":"9","key":"1914_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092147","volume":"14","author":"A Boquoi","year":"2022","unstructured":"Boquoi A, Rings V, Mohring A, Savickaite I, Zukovs R, Strapatsas J, et al. Opportunities for participation in randomised controlled trials for patients with multiple myeloma: trial access depends on restrictive eligibility criteria and patient expectations. Cancers (Basel). 2022;14(9):2147.","journal-title":"Cancers (Basel)"},{"key":"1914_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-3-319-42118-6_12","volume":"207","author":"S Brandhorst","year":"2016","unstructured":"Brandhorst S, Longo VD. Fasting and caloric restriction in cancer prevention and treatment. Recent Results Cancer Res. 2016;207:241\u201366.","journal-title":"Recent Results Cancer Res"},{"issue":"14","key":"1914_CR6","doi-asserted-by":"publisher","first-page":"11820","DOI":"10.18632\/oncotarget.3689","volume":"6","author":"I Caffa","year":"2015","unstructured":"Caffa I, D\u2019Agostino V, Damonte P, Soncini D, Cea M, Monacelli F, et al. Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. Oncotarget. 2015;6(14):11820\u201332.","journal-title":"Oncotarget"},{"issue":"18","key":"1914_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/nu14183851","volume":"14","author":"S Dal Bello","year":"2022","unstructured":"Dal Bello S, Valdemarin F, Martinuzzi D, Filippi F, Gigli GL, Valente M. Ketogenic diet in the treatment of gliomas and glioblastomas. Nutrients. 2022;14(18):3851.","journal-title":"Nutrients"},{"key":"1914_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2370-6","volume":"16","author":"TB Dorff","year":"2016","unstructured":"Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, et al. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016;16:360.","journal-title":"BMC Cancer"},{"issue":"26","key":"1914_CR9","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1056\/NEJMra1905136","volume":"381","author":"R de Cabo","year":"2019","unstructured":"de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019;381(26):2541\u201351.","journal-title":"N Engl J Med"},{"key":"1914_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1663-5","volume":"15","author":"S de Groot","year":"2015","unstructured":"de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomised pilot study. BMC Cancer. 2015;15:652.","journal-title":"BMC Cancer"},{"issue":"1","key":"1914_CR11","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1038\/s41467-020-16138-3","volume":"11","author":"S de Groot","year":"2020","unstructured":"de Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG, et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun. 2020;11(1):3083.","journal-title":"Nat Commun"},{"issue":"1","key":"1914_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccell.2016.06.019","volume":"30","author":"JM Englert","year":"2016","unstructured":"Englert JM, Powell JD. Hunger pains: stimulating the appetite of the immune system for cancer. Cancer Cell. 2016;30(1):13\u20135.","journal-title":"Cancer Cell"},{"issue":"23","key":"1914_CR13","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1182\/blood-2008-07-171389","volume":"113","author":"EB Golden","year":"2009","unstructured":"Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie SG, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009;113(23):5927\u201337.","journal-title":"Blood"},{"issue":"1","key":"1914_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3803\/EnM.2017.32.1.23","volume":"32","author":"Y Hwangbo","year":"2017","unstructured":"Hwangbo Y, Lee EK. Acute hyperglycemia associated with anti-cancer medication. Endocrinol Metab. 2017;32(1):23\u20139.","journal-title":"Endocrinol Metab"},{"key":"1914_CR15","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1158\/0008-5472.CAN-09-3228","volume":"70","author":"C Lee","year":"2010","unstructured":"Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010;70:1564\u201372.","journal-title":"Cancer Res"},{"issue":"1","key":"1914_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","volume":"11","author":"W Lei","year":"2025","unstructured":"Lei W, Zhou K, Lei Y, Li Q, Zhu H. Gut microbiota shapes cancer immunotherapy responses. NPJ Biofilms Microbiomes. 2025;11(1):143.","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"3","key":"1914_CR17","doi-asserted-by":"publisher","first-page":"100530","DOI":"10.1016\/j.medj.2024.10.007","volume":"6","author":"Y Lin","year":"2025","unstructured":"Lin Y, Xie M, Lau HC, Zeng R, Zhang R, Wang L, et al. Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response. Med. 2025;6(3):100530.","journal-title":"Med"},{"issue":"2","key":"1914_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cmet.2013.12.008","volume":"19","author":"VD Longo","year":"2014","unstructured":"Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014;19(2):181\u201392.","journal-title":"Cell Metab"},{"issue":"9","key":"1914_CR19","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.immuni.2023.07.002","volume":"56","author":"KM Luda","year":"2023","unstructured":"Luda KM, Longo J, Kitchen-Goosen SM, Duimstra LR, Ma EH, Watson MJ, et al. Ketolysis drives CD8+ T cell effector function through effects on histone acetylation. Immunity. 2023;56(9):2021-35.e8.","journal-title":"Immunity"},{"issue":"3","key":"1914_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/BF03343703","volume":"23","author":"G Murialdo","year":"2000","unstructured":"Murialdo G, Barreca A, Nobili F, Rollero A, Timossi G, Gianelli MV, et al. Dexamethasone effects on cortisol secretion in Alzheimer\u2019s disease: some clinical and hormonal features in suppressor and nonsuppressor patients. J Endocrinol Invest. 2000;23(3):178\u201386.","journal-title":"J Endocrinol Invest"},{"key":"1914_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41568-018-0061-0","volume":"18","author":"A Nencioni","year":"2018","unstructured":"Nencioni A, Caffa I, Cortellino S, Longo VD. Fasting and cancer: molecular mechanisms and clinical application. Nat Rev Cancer. 2018;18:707\u201319.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1914_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s42255-025-01287-w","volume":"7","author":"A Nobels","year":"2025","unstructured":"Nobels A, van Marcke C, Jordan BF, Van Hul M, Cani PD. The gut microbiome and cancer: from tumorigenesis to therapy. Nat Metab. 2025;7(5):895\u2013917.","journal-title":"Nat Metab"},{"issue":"1","key":"1914_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-025-01711-4","volume":"18","author":"I Ntanasis-Stathopoulos","year":"2024","unstructured":"Ntanasis-Stathopoulos I, Malandrakis P, Gavriatopoulou M. Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting. J Hematol Oncol. 2024;18(1):54.","journal-title":"J Hematol Oncol"},{"issue":"20","key":"1914_CR24","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1016\/j.cell.2025.06.018","volume":"188","author":"CM Phelps","year":"2025","unstructured":"Phelps CM, Willis NB, Duan T, Lee AH, Zhang Y, Rodriguez JDM, et al. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell. 2025;188(20):5680-5700.e28.","journal-title":"Cell"},{"issue":"5","key":"1914_CR25","doi-asserted-by":"publisher","DOI":"10.4142\/jvs.2020.21.e60","volume":"21","author":"A Pierini","year":"2020","unstructured":"Pierini A, Sartini I, Giorgi M, \u0141ebkowska-Wieruszewska B, Lisowski A, Poapolathep A, et al. Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. J Vet Sci. 2020;21(5):e60.","journal-title":"J Vet Sci"},{"issue":"24","key":"1914_CR26","doi-asserted-by":"publisher","first-page":"8215","DOI":"10.1073\/pnas.0708100105","volume":"105","author":"L Raffaghello","year":"2008","unstructured":"Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, et al. Starvation- dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A. 2008;105(24):8215\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1914_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100910","volume":"53","author":"J Rahmani","year":"2019","unstructured":"Rahmani J, Kord Varkaneh H, Clark C, Zand H, Bawadi H, Ryan PM, et al. The influence of fasting and energy restricting diets on IGF-1 levels in humans: A systematic review and meta-analysis. Ageing Res Rev. 2019;53:100910.","journal-title":"Ageing Res Rev"},{"issue":"21","key":"1914_CR28","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","volume":"38","author":"EJ Roeland","year":"2020","unstructured":"Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38(21):2438\u201353.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1914_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41579-024-01068-4","volume":"22","author":"FC Ross","year":"2024","unstructured":"Ross FC, Patangia D, Grimaud G, Lavelle A, Dempsey EM, Ross RP, et al. The interplay between diet and the gut microbiome: implications for health and disease. Nat Rev Microbiol. 2024;22(11):671\u201386.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"1914_CR30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.18632\/aging.100114","volume":"1","author":"FM Safdie","year":"2009","unstructured":"Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, et al. Fasting and cancer treatment in humans: a case series report. Aging (Albany NY). 2009;1(12):988\u20131007.","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"1914_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrmicro2974","volume":"11","author":"F Sommer","year":"2013","unstructured":"Sommer F, B\u00e4ckhed F. The gut microbiota--masters of host development and physiology. Nat Rev Microbiol. 2013;11(4):227\u201338.","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"1914_CR32","doi-asserted-by":"publisher","first-page":"e1660","DOI":"10.1093\/nutrit\/nuae105","volume":"83","author":"EJ Stringer","year":"2025","unstructured":"Stringer EJ, Cloke RWG, Van der Meer L, Murphy RA, Macpherson NA, Lum JJ. The Clinical Impact of Time-restricted Eating on Cancer: A Systematic Review. Nutr Rev. 2025;83(7):e1660\u201376.","journal-title":"Nutr Rev"},{"issue":"1","key":"1914_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/1099-081X(200001)21:1<33::AID-BDD213>3.0.CO;2-R","volume":"21","author":"SK Teo","year":"2000","unstructured":"Teo SK, Scheffler MR, Kook KA, Tracewell WG, Colburn WA, Stirling DI, et al. Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharm Drug Dispos. 2000;21(1):33\u201340.","journal-title":"Biopharm Drug Dispos"},{"issue":"7950","key":"1914_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05728-y","volume":"615","author":"J Tintelnot","year":"2023","unstructured":"Tintelnot J, Xu Y, Lesker TR, Sch\u00f6nlein M, Konczalla L, Giannou AD, et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature. 2023;615(7950):168\u201374.","journal-title":"Nature"},{"issue":"8","key":"1914_CR35","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.cmet.2024.06.014","volume":"36","author":"C Vernieri","year":"2024","unstructured":"Vernieri C, Ligorio F, Tripathy D, Longo VD. Cyclic fasting-mimicking diet in cancer treatment: preclinical and clinical evidence. Cell Metab. 2024;36(8):1644\u201367.","journal-title":"Cell Metab"},{"issue":"1","key":"1914_CR36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/1078-0432.CCR-05-0503","volume":"12","author":"W Zou","year":"2006","unstructured":"Zou W, Yue P, Lin N, He M, Zhou Z, Lonial S, et al. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res. 2006;12(1):273\u20138.","journal-title":"Clin Cancer Res"}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-026-01914-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-026-01914-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-026-01914-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:12:16Z","timestamp":1788423136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40814-026-01914-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1186\/s40814-026-01914-7","relation":{},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"130"}}